Evaluation and classification of drug therapy for breast cancer with bone-only metastasis
10.3760/cma.j.issn.0253-3766.2017.03.001
- VernacularTitle: 乳腺癌骨转移药物治疗的疗效评价及分类处理
- Author:
Xiangying MENG
1
;
Santai SONG
1
Author Information
1. Department of Breast Cancer, the Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China
- Publication Type:Review
- Keywords:
Breast neoplasms;
Neoplasms metastasis, bone;
Drug therapy;
Treatment outcome
- From:
Chinese Journal of Oncology
2017;39(3):161-165
- CountryChina
- Language:Chinese
-
Abstract:
Skeleton is one of the most common metastatic organs for breast cancer, which has a better prognosis than visceral metastases. Bone-only metastasis was defined"non-measurable" in the RECIST (Response Evaluation Criteria in Solid Tumors) criteria, and was excluded by clinical trials. However, patients with bone-only metastasis are also in need of effective treatment to prolong survival. Endocrine therapy is the most important treatment for bone metastatic patients. Tumor response of bone metastases can be determined objectively by bone-window CT. Effective treatment should be continued if the symptoms are relieved or osteogenesis is observed. Osteoblastic change in bone-window CT is a sign of improvement after treatment. Endocrine therapy is proper for ER-positive patients. The patients with initial osteoblastic metastasis should not be treated with salvage chemotherapy or anti-HER2 treatment, only if osteolytic metastasis or visceral metastasis is observed. Bishosphonates are just auxiliary drugs in bone metastasis, which should not be abused.
